尿路感染 尿路感染

Same author

Can We Do More for ISIM?

Journal of the Royal College of Physicians of London·2019

Same author

Towards the safer use of medicines.

BMJ (Clinical research ed.)·1995

Same author

Covert bacteriuria: long term follow up.

Archives of disease in childhood·1991

Same author

The yellow card: mark II.

BMJ (Clinical research ed.)·1991

Same author

Hypercalcaemia as a manifestation of malignant urothelial change in analgesic nephropathy.

Nephron·1989

Same author

Oral contraceptives and breast cancer.

British journal of cancer·1987

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026

Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026

相关实验视频

尿路感染尿路感染

相关概念视频

Can We Do More for ISIM?

Towards the safer use of medicines.

Covert bacteriuria: long term follow up.

The yellow card: mark II.

Hypercalcaemia as a manifestation of malignant urothelial change in analgesic nephropathy.

Oral contraceptives and breast cancer.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

相关实验视频

尿路感染 尿路感染

相关概念视频

相关文章

Can We Do More for ISIM?

Towards the safer use of medicines.

Covert bacteriuria: long term follow up.

The yellow card: mark II.

Hypercalcaemia as a manifestation of malignant urothelial change in analgesic nephropathy.

Oral contraceptives and breast cancer.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

尿路感染尿路感染